Skip to main content
LigaChem Biosciences Inc. logo

LigaChem Biosciences Inc. — Investor Relations & Filings

Ticker · 141080 ISIN · KR7141080002 KO Professional, scientific and technical activities
Open in API
Filings indexed 295 across all filing types
Latest filing 2019-08-05 Investor Presentation
Country KR South Korea
Listing KO 141080

About LigaChem Biosciences Inc.

https://ligachembio.com/

LigaChem Biosciences Inc. is a clinical-stage biopharmaceutical company specializing in the research and development of innovative medicines. Leveraging its core expertise in medicinal chemistry, the company focuses on developing Antibody-Drug Conjugates (ADCs), immuno-oncology drugs, and small molecules. A key asset is its proprietary, next-generation ADC platform technology, engineered to overcome the limitations of conventional ADC technologies. The company's pipeline includes multiple programs targeting oncology, as well as other therapeutic areas such as antibiotics and anti-fibrotics. LigaChem Biosciences actively pursues global drug development through strategic partnerships, including co-development and licensing agreements with international pharmaceutical companies.

Recent filings

Filing Released Lang Actions
기업설명회(IR)개최
Investor Presentation Classification · 98% confidence The document is a short regulatory announcement (under 1,000 characters) from Legochem Biosciences regarding the scheduling of an Investor Relations (IR) meeting (Non-Deal Roadshow). It provides logistical details such as date, location, and purpose, and mentions that materials will be distributed at the event or via the KRX website. Per the 'Menu vs Meal' rule, this is an announcement of an event/presentation rather than the presentation itself, and it fits the criteria for a general regulatory filing/announcement.
2019-08-05 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a Korean regulatory filing titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This is a standard disclosure form used by executives to report their personal share transactions (insider trading) to the Financial Supervisory Service and the Korea Exchange. Based on the provided definitions, this corresponds to 'Director's Dealing'.
2019-07-23 Korean
영업실적등에대한전망(공정공시)
Regulatory Filings Classification · 95% confidence The document is a 'Fair Disclosure' (공정공시) filing from LegoChem Biosciences regarding their financial performance outlook for the 2019 fiscal year. It provides specific revenue and operating profit projections and the basis for these estimates (milestone payments, licensing agreements). Since this is a forward-looking financial guidance announcement rather than a full quarterly/annual report or a simple report publication notice, it falls under the category of Management Reports (MDA), which covers management's explanation of business trends and outlook.
2019-07-23 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details changes in share ownership by major shareholders and special related parties (insiders). This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema.
2019-07-22 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 100% confidence The document is a 'Report of Large Shareholding' (주식등의 대량보유상황보고서), which is a regulatory filing required under the Capital Markets Act in South Korea when an individual or entity acquires a significant stake in a company. It details the reporter's identity, the number of shares held, and a chronological log of share transactions (buy/sell). This fits the definition of a 'Major Shareholding Notification'.
2019-07-19 Korean
기타경영사항(특허권취득)(자율공시)(항체-활성제 결합체 및 이의 제조 방법)
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure (자율공시) regarding the acquisition of a patent (특허권 취득) by LegoChem Biosciences. It details the patent name, content, and utilization plan. Since it is a regulatory announcement regarding a specific corporate event that does not fit into financial reporting, M&A, or governance categories, it falls under the general regulatory filing category.
2019-07-09 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.